Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …

Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …

PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis …

Purpose The MURANO study demonstrated significant progression-free survival (PFS)
benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in …

Disease overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
western countries. The disease typically occurs in elderly patients and has a highly variable …

The approval of venetoclax, a 'BH3-mimetic'antagonist of the BCL-2 anti-apoptotic protein,
for chronic lymphocytic leukemia represents a major milestone in translational apoptosis …

Accurate prediction of long-term outcomes remains a challenge in the care of cancer
patients. Due to the difficulty of serial tumor sampling, previous prediction tools have focused …

Assessment of measurable residual disease (often referred to as “minimal residual disease”)
has emerged as a highly sensitive indicator of disease burden during and at the end of …